AbbVie's $10.1 billion acquisition of ImmunoGen caps off a year of industry deals around antibody–drug conjugates, an area in which companies are continuing to explore new targets, linker technologies, and diverse warheads, emphasizing a commitment to refining the technology and improving treatment options for patients.

You do not currently have access to this content.